Weekender: Abbott capitalizes on digital health boom with virtual clinic for neuromodulation therapy

Signup | Forward Weekender March​ 13,​ 2021 | A roundup of this week's most read stories

Abbott capitalizes on digital health boom with virtual clinic for neuromodulation therapy The FDA-approved virtual clinic is the medtech giant's next step to gain share in the neurmod market from rivals Medtronic, Boston Scientific and Nevro. Quidel says COVID-19 test demand is plunging. Wall Street is underwhelmed. CEO Doug Bryant said demand plummeted between 30% and 40% in February and March compared to the fourth quarter, sending shares down 17% on Wednesday. FDA grants first EUA to at-home OTC molecular test for COVID-19 Cue Health received the emergency authorization and expects to be able to produce more than 100,000 tests a day by the summer, as the agency continues to prioritize more at-home testing options. Docs writing in NEJM push CMS to drop breakthrough payment rule Rescinding the rule would stop a change analysts saw as a "significant commercial tailwind" for companies including Abbott, J&J and Medtronic. Colfax to split in 2, creating over $1B orthopaedic player The split will create a medtech company with a portfolio of orthopaedic devices forecast to generate sales of around $1.4 billion this year. The move is expected to facilitate more M&A. Recommended For You Improve your recommendations: click here to update your profile. Deep Dive Hospitals lift curtain on prices, revealing giant swings for hips, knees and more At a Sutter hospital in San Francisco, a joint replacement ranges from $22,865 to $101,571, accordind to a Healthcare Dive analysis of data hospitals are required to report as of January.  Best of What We're Reading The Verge COVID-19 took disease tests out of the lab -- and may keep them there TCTMD LRT Trial Data Bolster Support for TAVI in Bicuspid Valves STAT 4 lessons from IBM’s failure to transform medicine with Watson Health BBC Covid-19: False test results 'ruining' return to school MobiHealthNews Cognito Therapeutics touts positive Phase 2 results for device-delivered Alzheimer's treatment TCTMD ‘Complete’ PCI Linked to Lower Mortality in Stable, Multivessel CAD: Registry Suggest a story we should read Dive Into a Topic Medical Devices Policy & Regulation Clinical Trials Manufacturing Legal M&A Research Diagnostics Digital Health Imaging Share MedTech Dive: Daily Dive with others and get rewarded. You've referred 0 readers. To become an official Dive Insider, just successfully refer 10 contacts to MedTech Dive: Daily Dive. Here's your link to share: https://www.medtechdive.com/signup/insiders/?signup_referred_by=5f93078d7aa51972095c9316

More Than A Newsletter Related Publications BioPharma Dive | Healthcare Dive Connect With Us Twitter | LinkedIn Editorial Contact an editor | Meet the team Advertising Contact our team About MedTech Dive MedTech Dive provides in-depth journalism and insight into the most impactful news and trends shaping medical technology. The newsletters and website cover topics such as medical devices, diagnostics, digital health, regulation/compliance, R&D, M&A and more. Medtech Dive is a leading publication operated by Industry Dive. Our business journalists spark ideas and shape agendas for 10+ million decision makers in competitive industries. Sign up for the newsletter This email is optimized for display on mobile phones. MedTech Dive: Daily Dive is a product of Industry Dive, Inc. 1255​ 23rd Street NW, Suite 550, Washington,​ DC 20037. We value your privacy. We won't share your email address with anyone else without your permission. This message was sent to edwardlorilla1986.acciyo123@blogger.com. You can unsubscribe or switch to a weekly newsletter subscription anytime. See our full privacy policy.

Sign up | Manage subscription | Advertise with us | Submit story tip